trending Market Intelligence /marketintelligence/en/news-insights/trending/mxa9fidvdl866tmamwdnqq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

GSK's shingles vaccine wins approval in Europe, Japan

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

GSK's shingles vaccine wins approval in Europe, Japan

The European Commission and the Japanese Ministry of Health, Labour and Welfare approved GlaxoSmithKline Plc's shingles vaccine Shingrix for use in adults 50 years old and above.

Shingles, or herpes zoster, is a painful rash that develops on one side of the face or body caused by the varicella-zoster virus, the same virus that causes chickenpox.

In Europe, the vaccine is also indicated to prevent post-herpetic neuralgia in the same patient age group. Post-herpetic neuralgia is a common complication of shingles characterized by chronic nerve pain in the rash areas.

The approval was backed up by the results of a phase 3 trial where the vaccine showed a 90% effectiveness against shingles.

Shingrix received approval from the U.S. Food and Drug Administration in October 2017.